Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope and definitions
1.3 Base estimates and working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Pharmacovigilance industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Type trends
2.1.3 Clinical trial phase trends
2.1.4 Service provider trends
2.1.5 End-user trends
2.1.6 Regional trends
Chapter 3 Pharmacovigilance Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 – 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing need of new drugs
3.3.1.2 Rising investment on R&D by pharmaceutical companies
3.3.1.3 Rise in incidences of adverse drug reactions (ADR) and drug toxicity
3.3.1.4 Increasing focus on personalized medicine
3.3.1.5 Increasing trend of outsourcing pharmacovigilance services
3.3.2 Industry pitfalls & challenges
3.3.2.1 High risk associated with data security
3.3.2.2 Lack of skilled healthcare professionals
3.4 Growth potential analysis
3.4.1 By type
3.4.2 By clinical trial phase
3.4.3 By service provider
3.4.4 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Technology landscape
3.7.1 Artificial intelligence (AI) in pharmacovigilance
3.7.2 Natural language processing (NLP) in pharmacovigilance
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix
4.4 Competitive analysis of major market players
4.5 Strategic outlook matrix
4.6 Company market share analysis, 2022
4.7 Strategy dashboard, 2022
Chapter 5 Pharmacovigilance Market, By Type
5.1 Key type trends
5.2 Software
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Service
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.2 By Process
5.3.2.1 Core services
5.3.2.1.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.2.2 Consulting services
5.3.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.3 By Activity
5.3.3.1 Spontaneous Reporting
5.3.3.1.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.3.2 Intensified Adverse Drug Reaction (ADR) Reporting
5.3.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.3.3 Cohort Event Monitoring
5.3.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.3.4 EHR Mining
5.3.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.3.5 Others
5.3.3.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Pharmacovigilance Market, By Clinical Trial Phase
6.1 Key clinical trial phase trends
6.2 Pre-clinical
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Phase 1
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Phase 2
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Phase 3
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Phase 4
6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Pharmacovigilance Market, By Service Provider
7.1 Key service provider trends
7.2 In-house
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Contract outsourcing
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Pharmacovigilance Market, By End-use
8.1 Key end-use trends
8.2 Pharmaceutical & biotechnological companies
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Medical device companies
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.4 Hospitals
8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.5 Others
8.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Pharmacovigilance Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Qatar
9.6.5 Israel
9.6.6 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Accenture
10.2 Cognizant
10.3 Labcorp Drug Development
10.4 IBM Corporation
10.5 ArisGlobal
10.6 ICON plc
10.7 United BioSource LLC
10.8 Pharmaceutical Development Group, Inc.
10.9 Wipro Limited
10.10 Allucent
